Jump to content

Understanding the Impact of Upstream and Downstream Process Changes on an Integrating AAV Vector with NGS

In this webinar, William Lee from Alexion Pharmaceuticals presents the importance of well-developed assays that can detect changes in critical quality attributes of AAV vectors. He compares 3 different manufacturing processes and describes optimizations introduced to obtain a therapeutic product of the highest quality and at a high yield. He describes analytical procedures, such as nanopore sequencing, to assess the differences between the batches such as potency, purity and more.

This talk was given as part of our regular Open Forums on NGS-based QC for AAV Vectors.

Who should watch?

Biopharma and biotech professionals looking to advance analytical development, biosafety, and QC testing for CGT products by embracing digitalization and innovative enterprise data analysis systems.

Request Resource

By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Genedata privacy policy